9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Condition Mesothelioma Estimated Enrollment: 30 Age Group: 18 Years to 100 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment Study ID Numbers: 160127|16-C-0127 Study First Received: June 10, 2016 Last Updated: April 20, 2017 Estimated Primary Completion Date: August 6, 2018 Primary Outcome Measures: maximum tolerated dose|proportion of patients at MTD with paartial or complete response per RECIST|average time from treatment initiaition to disease progression or death|average time from start of treatment to death|pharmacokenetic characteristics|number of cycles LMB-100 can be given before ADAs develop|listing and frequency of treatment related adverse events Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center...

Continue reading

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

Condition Mesothelioma Estimated Enrollment: 36 Age Group: 18 Years to 80 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other Study ID Numbers: H-36460 Study First Received: July 16, 2016 Last Updated: March 24, 2017 Estimated Primary Completion Date: July 2018 Primary Outcome Measures: Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma. Sponsors and Collaborators: Baylor College of Medicine Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02838745...

Continue reading

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Condition Mesothelioma Estimated Enrollment: 1000 Age Group: 2 Years to 100 Years   (Child, Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: 130202|13-C-0202 Study First Received: September 21, 2013 Last Updated: April 21, 2017 Estimated Primary Completion Date: July 25, 2033 Primary Outcome Measures: Allow sample acquisition for use in the study of mesothelioma Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01950572...

Continue reading

Trial of Adcetris in CD30+ Malignant Mesothelioma

Condition Lung Diseases Due to External Agents|Mesothelioma Estimated Enrollment: 50 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2016-0514|NCI-2017-00069 Study First Received: December 28, 2016 Last Updated: April 19, 2017 Estimated Primary Completion Date: April 2022 Primary Outcome Measures: Disease Control Rate (DCR) in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin|Time to Progression in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin Sponsors and Collaborators: M.D. Anderson Cancer Center|Seattle Genetics, Inc. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT03007030...

Continue reading

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma|Mesothelioma Estimated Enrollment: 36 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: MCC-18094 Study First Received: November 18, 2015 Last Updated: February 21, 2017 Estimated Primary Completion Date: January 2018 Primary Outcome Measures: Objective Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)|Occurrence of Treatment Related Toxicity|Quality of Life Questionnaire Scores Sponsors and Collaborators: H. Lee Moffitt Cancer Center and Research Institute Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02611037...

Continue reading